Opinion|Videos|March 19, 2025
Adjuvant ICI for High-Risk MIUC: AE Monitoring and Management
Author(s)Matthew Galsky, MD
An expert discusses how medical professionals monitor and manage adverse events (AEs) with adjuvant nivolumab through regular assessments, including laboratory tests and clinical evaluations. While approaches may overlap with metastatic settings, adjuvant treatment often emphasizes early detection of immune-related AEs, as patients are generally healthier.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is your approach to AE monitoring and management with adjuvant nivolumab? Does your approach differ at all in adjuvant vs metastatic setting?
Advertisement
Related to this article
Oncologists weigh second-line options after IO/TKI failure in metastatic ccRCC, highlighting tolerability, mechanism shifts, and belzutifan’s broader role.
In the phase 3 EMBER-3 trial, imlunestrant plus abemaciclib doubled median progression-free survival vs imlunestrant alone in ESR1-mutated advanced breast cancer.
CELESTIMO trial shows mosunetuzumab plus lenalidomide boosts PFS in relapsed follicular lymphoma, supporting earlier-line outpatient, chemo-free care.
The FDA's Expedited Investigational New Drug (IND) Pilot Program pairs trial sponsors and research institutions to promote phase 1 trials in the US.
During a live event, Sikander Ailawadhi, MD, and participants considered a case patient with relapsed multiple myeloma after a quadruplet induction who declined CAR T-cell therapy.
FDA clears Triton 1 robotic colonoscopy for screening and advanced therapy, backed by first-in-human data showing high detection rates and reduced clinician workload.
Results from the phase 3 MAVERICK trial (SWOG S1827) show MRI surveillance alone improved cognitive failure-free survival vs adding PCI in SCLC.
The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
2
Data Increasingly Favor BCMA-Directed Therapy For Early-Relapse Myeloma
3
Sub-Q Amivantamab and Supportive Care Minimize Discontinuation in EGFR+ NSCLC
4
FDA Clears Robotic System for Endoscopic Procedures in the Colon
5